21.10.2019Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it intends to offer $500 million in aggregate principal amount of senior notes due 2028 (the “notes”) in an unregistered offering, subject to market conditions. Charles River intends to use the net proceeds of the notes offering and cash on hand to prepay a portion of its term loan facility under its senior credit facilities and to pay related fees and expenses. (...)
21.10.2019Rheos Medicines, a biopharmaceutical company harnessing insights in immunometabolism to create a new class of therapeutics for patients with severe autoimmune disorders, inflammatory diseases and cancer, today announced the appointment of industry veteran Barbara S. Fox, Ph.D., to Chief Executive Officer. Dr. Fox succeeds interim Chief Executive Officer, Abbie Celniker, Ph.D., a partner at Third Rock Ventures, who will remain Chairman of Rheos Medicines’ board (...)
21.10.2019Aerpio Pharmaceuticals, Inc. (NasdaqCM: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular disease and diabetic complications, today announced that its Board of Directors has initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value from the Company’s clinical assets and cash resources, which amounted to $48.2 million as of June 30, 2019. (...)
21.10.2019Sartorius Stedim Biotech (SSB) (Paris:DIM) has agreed to acquire parts of Danaher’s Life Science portfolio as part of a broader transaction between Danaher and Sartorius Group, SSB’s major shareholder. The total purchase price is approximately $750 million in cash of which about a quarter will be allocated to the businesses purchased by SSB. The final purchase price allocation will be subject to the closing process. (...)
21.10.2019Der bayerische Vorgründungs-Wettbewerb m4 Award unterstützt Gründungen für die Präzisionsmedizin – die Medizin der Zukunft / Der bayerische Vorgründungs-Wettbewerb m4 Award gibt aktuell die Gewinner bekannt. / Onkologie und Antibiotika-Resistenzen sind die Themen des diesjährigen m4 Award. / 2,5 Millionen Euro Förderung für innovative Projekte zur Entwicklung neuer Wirkstoffe gegen Erkrankungen mit einem hohen medizinischen Bedarf. (...)
21.10.2019UDI-Lasermarkierung als Gesamtpaket / Auf der Medica, einer der wichtigsten internationalen Medizintechnik-Messen (Messe Düsseldorf, 18. - 21. November 2019), ist FOBA mit seinen kamerabasierten Markierarbeitsplätzen der M-Serie vertreten, die sich für die UDI-Markierung besonders bewährt haben. FOBA bietet, basierend auf jahrzehntelanger Expertise mit Schwerpunkt Medizinindustrie, einen ganzheitlichen Markierprozess, der nicht nur innovative technische Lösungen, sondern auch die Validierung der Zeichen, die Qualifizierung von Prozess und Maschinen sowie Beratung und Service umfasst. (...)
21.10.2019Verfahren von Forschern der TU Wien hat Druckgeschwindigkeit von einem Meter pro Sekunde / Forscher der Technischen Universität Wien (TU Wien) http://tuwien.at haben ein neues Bioprinting-Verfahren entwickelt, mit dem sich lebende Zellen in feine Strukturen aus dem 3D-Drucker einbauen lassen - und das mit einer Druckgeschwindigkeit von einem Meter pro Sekunde. Das ist laut den Experten eine Größenordnung, die bisher nicht möglich war. (...)
22.10.2019LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, has completed its acquisition of the diagnostic clinical laboratory testing business of South Bend Medical Foundation (SBMF), considerably enhancing the scope of local services that LabCorp offers to hospitals, physicians, and patients across Indiana, Michigan, Ohio, and Illinois. In addition, LabCorp and SBMF will collaborate to provide integrated (...)
22.10.2019SpendEdge, a global procurement market intelligence firm, has announced the release of its Global Pharmaceutical Excipients Market - Procurement Intelligence Report. According to the forecasts, the pharmaceutical excipients market is set to expect a category spend growth of over USD 2 billion between 2018-2023. The growing acceptance of biologics and biosimilars will favor the demand growth in the pharmaceutical excipients market to a significant extent. With counterfeit medicines doing the round, pharmaceutical excipients will find their extensive application in identifying counterfeit drugs. (...)
22.10.2019bluebird bio, Inc. (Nasdaq: BLUE) announced today that the European Medicines Agency (EMA) approved the refined commercial drug product manufacturing specifications for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene), a one-time gene therapy for patients 12 years and older with transfusion-dependent β-thalassemia (TDT) who do not have a β0/β0 genotype, for whom hematopoietic stem cell (HSC) transplantation is appropriate but a human leukocyte antigen (HLA)-matched related HSC donor is not available. (...)
Sie sehen Artikel 7411 bis 7420 von insgesamt 23543